Partial recovery of erythrocyte glycogen in diabetic rats treated with phenobarbital.
Erythrocytes may play a role in glucose homeostasis during the postprandial period. Erythrocytes from diabetic patients are defective in glucose transport and metabolism, functions that may affect glycogen storage. Phenobarbital, a hepatic enzyme inducer, has been used in the treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM), increasing the insulin-mediated glucose disposal. We studied the effects of phenobarbital treatment in vivo on glycemia and erythrocyte glycogen content in control and alloxan-diabetic rats during the postprandial period. In control rats (blood glucose, 73 to 111 mg/dl in femoral and suprahepatic veins) the erythrocyte glycogen content was 45.4 +/- 1.1 and 39.1 +/- 0.8 micrograms/g Hb (mean +/- SEM, N = 4-6) in the femoral artery and vein, respectively, and 37.9 +/- 1.1 in the portal vein and 47.5 +/- 0.9 in the suprahepatic vein. Diabetic rats (blood glucose, 300-350 mg/dl) presented low (P < 0.05) erythrocyte glycogen content, i.e., 9.6 +/- 0.1 and 7.1 +/- 0.7 micrograms/g Hb in the femoral artery and vein, respectively, and 10.0 +/- 0.7 and 10.7 +/- 0.5 in the portal and suprahepatic veins, respectively. After 10 days of treatment, phenobarbital (0.5 mg/ml in the drinking water) did not change blood glucose or erythrocyte glycogen content in control rats. In diabetic rats, however, it lowered (P < 0.05) blood glucose in the femoral artery (from 305 +/- 18 to 204 +/- 45 mg/dl) and femoral vein (from 300 +/- 11 to 174 +/- 48 mg/dl) and suprahepatic vein (from 350 +/- 10 to 174 +/- 42 mg/ dl), but the reduction was not sufficient for complete recovery. Phenobarbital also stimulated the glycogen synthesis, leading to a partial recovery of glycogen stores in erythrocytes. In treated rats, erythrocyte glycogen content increased to 20.7 +/- 3.8 micrograms/g Hb in the femoral artery and 30.9 +/- 0.9 micrograms/g Hb in the suprahepatic vein (P < 0.05). These data indicate that phenobarbital activated some of the insulin-stimulated glucose metabolism steps which were depressed in diabetic erythrocytes, supporting the view that erythrocytes participate in glucose homeostasis.
da-Silva
C A
CA
Departamento de Fisiologia e Bioffsica, Universidade Estadual de Campinas, SP, Brasil.
Gonçalves
A A
AA
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism*; D004912:Erythrocytes / Q000378:metabolism*; D014453:Glucuronosyltransferase / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism*; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D008297:Male; D010634:Phenobarbital / Q000494:pharmacology* / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
D006993:Hypnotics and Sedatives; D006003:Glycogen; D014453:Glucuronosyltransferase; D010634:Phenobarbital